Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
Q1 2026 vs. Q4 2025
How the institutions holding Liminatus Pharma, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 12 | 1 | 15 | +4 |
| Shares | 317.2K | 73.4K | 1.48M | +1.23M (+505.3%) |
| Value | $193.5K | $44.8K | $253.8K | +$105.0K (+70.6%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Liminatus Pharma, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cygnus Capital Advisors, LLC | 350,000 | $60.0K | 0.04% |
| Jane Street Group, LLC | 71,318 | $12.3K | 0.00% |
| Vanguard Capital Management LLC | 50,440 | $8.68K | 0.00% |
| JustInvest LLC | 34,706 | $5.97K | 0.00% |
| Virtu Financial LLC | 27,468 | $5.00K | 0.00% |
| Vanguard Fiduciary Trust Co | 22,984 | $3.95K | 0.00% |
Sold out (2)
Institutions that held Liminatus Pharma, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Two Sigma Investments, LP | 35,284 | $21.5K |
| Bank of America Corp | 44 | $27 |
Not filed for Q1 2026 yet (1)
Institutions that held Liminatus Pharma, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 73,424 | $44.8K |